Hirofumi Osada
Showa University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hirofumi Osada.
Journal of Cardiovascular Pharmacology | 2002
Hiroaki Shimokawa; Katsuhiko Hiramori; Hiroyuki Iinuma; Saichi Hosoda; Hiroshi Kishida; Hirofumi Osada; Takashi Katagiri; Kazunobu Yamauchi; Yoshiki Yui; Takazo Minamino; Mitsuyoshi Nakashima; Kazuzo Kato
Rho-kinase plays an important role in calcium sensitization for vascular smooth muscle (VSMC) contraction and may be involved in the inappropriate coronary vasoconstriction during exercise-induced myocardial ischemia. In this multicenter phase II study, the anti-anginal effect of fasudil, which is metabolized to a specific Rho-kinase inhibitor hydroxyfasudil after oral administration, was examined in patients with stable effort angina. In the phase IIa trial, after a 2-week washout period of anti-anginal drugs, 45 patients received increasing doses of fasudil (5, 10, and 20 mg TID for every 2 weeks). The fasudil treatment significantly prolonged the maximum exercise time and the time to the onset of 1-mm ST segment depression on treadmill exercise test (both p < 0.01), whereas blood pressure and heart rate during exercise were unchanged before and after the treatment. Higher doses of fasudil (20 and 40 mg TID) were subsequently tested in 22 patients in the same manner with similar positive results. In the phase IIb trial, after a 2-week washout period of anti-anginal drugs, 125 patients were assigned, in a double-blind manner, to a 4-week oral treatment with a different dose of fasudil (5, 10, 20, or 40 mg TID) and treadmill exercise test was performed before and after the treatment. Again, both maximum exercise time and time to the onset of 1-mm ST segment depression were prolonged in all groups. A significant dose-response relation was noted across the treatment groups for the exercise tolerance index that was determined by the combined effect of exercise time and ST segment depression (p = 0.006). Fasudil was well tolerated in both trials without any serious adverse reactions. These results suggest the efficacy and adequate safety profile of fasudil, the first drug in a novel class of vasodilators, for the treatment of stable effort angina.
Clinical and Experimental Pharmacology and Physiology | 1995
Tomoe Nakata; Sadayuki Sato; Mitsugu Hachisu; Takeshi Tsutsumi; Hirofumi Osada
1. The slow inward Ca2+ current elicited at the membrane potential ‐ 30 mV in SHR and normotensive Wistar rats (WR) with voltage‐clamp recording was examined for this study.
Japanese Heart Journal | 1992
Masafumi Kasama; Masahiro Nakayama; Kazuhiko Shimizu; Yukei Higashi; Junichi Nagashima; Hiroshi Tsunakawa; Hirofumi Osada; Saburo Mashima
Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics | 1989
Yawara Yoshitoshi; Noboru Yamazaki; Osamu Iimura; Hirokazu Niitani; Kizuku Kuramoto; Hirofumi Osada; Yasushi Mizuno; Iwao Sotobata; Hironori Toshima; Mitsuyoshi Nakashima
Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics | 2004
Hajime Ide; Takeshi Tsutsumi; Youichi Takeyama; Hirofumi Osada
Japanese Heart Journal | 1990
Takeshi Tsutsumi; Souichiro Sekiya; Yuukei Higashi; Hirofumi Osada; Tomoe Nakada; Sadayuki Sato
Rinsho Yakuri\/japanese Journal of Clinical Pharmacology and Therapeutics | 1999
Keiichi Kajihara; Takeshi Tsutsumi; Hirofumi Osada; Youichi Takeyama; Atsuro Iwasawa; Yoshiko Nakamura
Japanese Heart Journal | 1997
Kenji Yoshino; Masataka Kazama; Tae Hitoto; Aiko Matsui; Yoichiro Matsui; Takeshi Tsutsumi; Hirofumi Osada
Japanese Heart Journal | 1997
Keiichi Kazihara; Takeshi Tsutsumi; Yutaka Shimizu; Hirofumi Osada; Saburo Mashima; Atsuo Iwasawa; Yoshiko Nakamura
Shinzo | 1996
Takeshi Tsutsumi; Keiichi Kajihara; Yutaka Shimizu; Li-zhi Li; Hirofumi Osada; Saburo Mashima; Atsuo Iwasawa; Yoshiko Nakamura